Mankind Pharma, through its Dutch subsidiary, signed a definitive agreement to invest EUR48 million for a 70% stake in Armed Cell Therapeutics. The newly formed Belgian company holds a preclinical portfolio of multi-targeting and…
FDA cleared Legend Biotech’s IND for LB2501, an investigational single-infusion in vivo CAR-T therapy designed to generate dual CD19/CD20-targeting T cells inside the patient. Legend describes it as the first known dual-targeting in vivo…
FDA cleared IASO208, a CD20-directed in vivo CAR-T candidate built on a replication-incompetent, self-inactivating third-generation lentiviral vector, for U.S. clinical testing in adults with relapsed or refractory B-cell non-Hodgkin lymphoma. IASO Bio expects to…
Typewriter Therapeutics emerged from stealth with a $56 million Series A led by AN Venture Partners and RA Capital Management. The Cambridge-Tokyo startup is developing a two-component, lipid-nanoparticle-delivered RNA system intended to insert full…
ArsenalBio is shifting its primary focus from clinical autologous solid-tumor cell therapies to in-vivo CAR-T programs spanning hematologic malignancies, autoimmunity and other chronic disease. The private company disclosed a substantial workforce reduction, retaining a…
Adicet disclosed FDA clearance of the ADI-212 IND for metastatic castration-resistant prostate cancer and unveiled an in-vivo CAR-T portfolio spanning multiple myeloma, non-Hodgkin lymphoma and solid tumors. ADI-212 is described as an off-the-shelf, gene-edited,…
CREATE Medicines and WestGene entered an R&D and licensing collaboration combining WestGene’s targeted lipid nanoparticle delivery technology with CREATE’s in vivo immune-cell programming platform, aiming to advance dual-targeted and durable in vivo CAR constructs…
